Literature DB >> 3549324

Genetic variation in the human hepatic cytochrome P-450 system.

W Kalow.   

Abstract

Studies in rodents indicate that the cytochrome P-450 system consists of a superfamily of heme proteins, produced by clusters of structural genes on different chromosomes. Equivalent P-450s of different species show more homologies than members of different P-450 families within a species. The Ah receptor serves the induction of members of one of the cytochrome families. The human structural gene for the methylcholanthrene-inducible P1-450 is located on Chromosome 15. This gene has been completely sequenced. The human Ah receptor is also measurable. New methods to measure inducibility in man involve new lymphocyte bioassays and mRNA determinations, while in vivo biotransformation studies of caffeine allow estimates of the state of induction. Structural genes for phenobarbital-inducible cytochromes have been localized to Chromosome 19. The deficiency of biotransformation of debrisoquine and sparteine continues to be explored intensely. Linkage studies indicate the gene for the variable cytochrome P-450 to be located on Chromosome 22. The deficiency is more likely due to structural variation than absence of the cytochrome. Inhibiting drugs can mimic the genetic defect. Many pharmacological and toxicological consequences of the deficiency have been defined. The main characteristics of the genetic deficiencies affecting the metabolisms of mephenytoin, phenytoin, tolbutamide, nifedipine and of methyl cysteine were outlined briefly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549324     DOI: 10.1007/BF00541288

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  51 in total

1.  The influence of enzyme induction on polymorphic sparteine oxidation.

Authors:  M Eichelbaum; S Mineshita; E E Ohnhaus; C Zekorn
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  The genetic polymorphism of sparteine metabolism.

Authors:  M Eichelbaum; K P Reetz; E K Schmidt; C Zekorn
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

3.  Two RFLPs associated with the human P1450 gene linked to the MPI locus on chromosome 15 [HGM8 D15S8].

Authors:  A K Jaiswal; D W Nebert
Journal:  Nucleic Acids Res       Date:  1986-05-27       Impact factor: 16.971

4.  [Phenytoin poisoning in a degradation disorder, report of a case with cerebellar atrophy].

Authors:  T Feuerstein; G M von Reutern; H Cramer
Journal:  Nervenarzt       Date:  1983-02       Impact factor: 1.214

5.  Impairment of phenytoin parahydroxylation as a cause of severe intoxication.

Authors:  F A de Wolff; P Vermeij; M D Ferrari; O J Buruma; D D Breimer
Journal:  Ther Drug Monit       Date:  1983-06       Impact factor: 3.681

Review 6.  Oral hypoglycaemic agents. An update.

Authors:  A C Asmal; A Marble
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

7.  The genetic defect of mephenytoin hydroxylation.

Authors:  W Kalow
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

8.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

Authors:  C Nordin; B Siwers; J Benitez; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

9.  Expression and chromosomal localization of the cytochrome P1-450 gene in human mitogen-stimulated lymphocytes.

Authors:  S C Amsbaugh; J H Ding; D C Swan; N C Popescu; Y T Chen
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

10.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

View more
  22 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.

Authors:  J Kallio; R Huupponen; K Pyykkö
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration.

Authors:  J van Harten; J Burggraaf; M Danhof; P van Brummelen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

5.  Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.

Authors:  P A Philip; L D Lewis; C A James; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 6.  [The development of pharmacogenetics--a retrospective on the 75th birthday of Hans Herken].

Authors:  W Kalow
Journal:  Klin Wochenschr       Date:  1988-03-15

7.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.

Authors:  N H Shear; S P Spielberg
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

8.  Induction of P-450 in workers exposed to dioxin.

Authors:  W Halperin; W Kalow; M H Sweeney; B K Tang; M Fingerhut; B Timpkins; K Wille
Journal:  Occup Environ Med       Date:  1995-02       Impact factor: 4.402

9.  Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.

Authors:  J Kallio; R Lindberg; R Huupponen; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

10.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

Authors:  G Muralidharan; E M Hawes; G McKay; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.